問卷

TPIDB > Principal Investigator

Principal Investigator


Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung (在職)

Division of Urology

Division of Urology

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of Urology

更新時間:2023-09-19

吳俊德
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

34Cases

2025-09-15 - 2036-04-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-05-03 - 2028-01-10

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-05-01 - 2029-03-06

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-06-03 - 2030-04-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-02-03 - 2033-05-03

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-08-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-01-26 - 2029-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-30 - 2032-05-01

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2014-10-01 - 2024-12-30

Phase II

A PHASE II, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MCS® IN PROSTATE CANCER PREVENTION
  • Condition/Disease

    PROSTATE CANCER

  • Test Drug

    MCS®

Participate Sites
21Sites

Recruiting6Sites

Study ended15Sites

1 2 3 4